Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We should see these results any day now! October 2021 completion date!
THIS WILL BE BIG NEWS!
Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19
ClinicalTrials.gov Identifier: NCT04771351
Recruitment Status : Recruiting
First Posted : February 25, 2021
Last Update Posted : April 12, 2021
Brief Summary:
This is a placebo-controlled study to investigate the safety and efficacy of a single injection of COVI-AMG in inpatient adults with COVID-19.
Covid19
Biological: COVI-AMG
Drug: Placebo
Phase 2
Detailed Description:
This is a multi-center, randomized, double-blind, placebo-controlled study designed to investigate the safety and efficacy of a single injection of COVI-AMG in inpatient adults with COVID-19. Subjects will receive 100 mg of COVI-AMG, 200 mg of COVI-AMG, or placebo via slow IV push. Subjects will be followed for approximately 70 days post dosing.
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 280 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Blinded-controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adult Patients With COVID-19
Estimated Study Start Date : April 2021
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : October 2021
COVISTIX approved for sale in MEXICO.
Then approved for sale in EUROPE.
Now approved in BRAZIL.
Next comes CANADA.
And finally the US! Potential market size ~2 Billion.
Dr. Henry Ji, Chairman and CEO of Sorrento. “We look forward to working even more closely with the government to help deploy our test at large scale. We have been building our manufacturing capacity in anticipation of EUA clearances in multiple countries in need of highly sensitive, and simple COVID-19 rapid antigen testing.”
Potential sales? $ BILLIONS!
STIX / ABIVERTINIB / SP102 / DROPS
All have near term news. All have billion dollar markets.
The other 72+ Sorrento programs can be financed by the profits from these 4 programs alone. I was glad to see the new updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered.China NDA filed for cervical cancer.
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico and Europe...millions shipped to Mexico.Brazil,WHO and Canada coming soon. DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel phase 1b
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of ImmunityBio, Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks in Mexico. Outstanding ABIVERTINIB(COVID) results in Brazil and US. And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
China is the largest single pharmaceutical market in the world. Who cares ? The Big Pharmas do...and Sorrento having a toe in that market makes it all the more impressive for partnerships or the inevitable buyout.
Sorrento can still apply for EUA's in Brazil and the US for ABIVERTINIB(COVID). The pivotal phase 3 will then be for longer term approval.
COVIDROPS and COVI-MSC are in phase 2 trials(both safety and efficacy). They too could receive EUA's on the basis of interim analysis if the results are so good that it is unfair to placebo patients to deny them access to these trial drugs!
In any case look to rapid enrollment in Sorrento Covid trials as word spreads about the fine results in the ABIVERTINIB trials!
Both ABIVERTINIB Covid studies used a 9-point ordinal scale as follows: (0) nonhospitalized and no clinical or virological evidence of infection; (1) nonhospitalized and no limitation on activities; (2) nonhospitalized, but with limitation on activities; (3) hospitalized, but not requiring supplemental oxygen; (4) hospitalized and on oxygen via mask or nasal prongs; (5) hospitalized, on noninvasive ventilation or high-flow oxygen or pressure support ventilation in weaning mode; (6) hospitalized, intubated and on MV; (7) hospitalized on MV and additional organ support (renal replacement therapy, vasoactive drugs or extracorporeal membrane oxygenation), and (8) dead.
Sorrento has trials underway for each stage of COVID. Just guessing but could be...
COVIDROPS for status 1-3.
ABIVERTINIB for status 4-5.
COVI-MSC for status 5-7.
And how about ABIVERTINIB and COVI-MSC combinations?
It is interesting to compare the results of the Brazilian study of ABIVERTINIB to a Brazilian study of the highly touted drug chloroquine/hydroxychloroquine. While ABIVERTINIB proved to be about 55% more effective than SOC in status 5 patients the chloro/hydrochloro study was ended early "...DUE TO HARMFUL EFFECTS. Patients in the intervention group had a worse clinical outcome..."
See the study published April 27,2021
https://www.nature.com/articles/s41598-021-88509-9
Compare Sorrento's results to AZ's Nov.12, 2020...
AZ’s BTK inhibitor Calquence fails in COVID-19 study
Therapy is already approved to treat a number of blood cancers
"AstraZenea’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence has failed to improve survival and prevent respiratory failure in hospitalised COVID-19 patients.
The CALAVI phase 2 trials had been evaluating the efficacy and safety of Calquence (acalabrutinib) alongside best supportive care (BCS) in patients hospitalised with respiratory complications of COVID-19.
The primary endpoint, measuring respiratory failure or death, was not met, with the addition of Calquence to BCS failing to increase the number of patients who remained alive and free of respiratory failure compared to placebo.""
Important post by a Biostatistician
rashedul...
I send the following email to them about their wrong misleading PR:
We are awaiting for the Phase 2 results and we got that. After checking the update, I was shocked as I am a Biostatistician. Your PR team and Biostat team did a poor job! You should not keep them to uphold investors rights.
Let me calculate the math for you. In Clinical RCT studies, all we care about is the relative change between Treatment (Abivertinib) and Control.
In the US Phase II study (n=96), your improvement (survival at 1 month) was 78.3% for Abivertinib vs. 58.3% for Control. You wrote 20% improvement (?). How? Respect to what? Actually, what you should report is the relative improvement for Abivertinib compared to Control which is 78.3/58.3 = 1.343 implying Abivertinib brought (1.343-1) =34.3% more improvement (survival at 1 month) when compared to Control! HUGE clinical result! Each 1 of 3 deaths could be averted if Abivertinib is used! And you wrote merely 20%? You should interpret it properly.
Similarly, for Brazil study (n=400), the results are better. Mind blowing! The relative improvement there was 69.6/44.4 = 1.568 implying Abivertinib brought (1.568-1) =56.8% more improvement (survival at 1 month) when compared to Control!but you report 25%? Why? Around 6 out of 10 such deaths could be averted by using Abivertinibis! This is a result the whole world is looking for!!
Clinically and statistically, the results make total sense. Large sample (n=400) gives a larger effect size. And, more confident breakthrough results!! You should definitely work with your PR and Stats team. As a Biostatistician, I can also help you. I am doing those works regularly!
And we investors are taking the hit because of those poor PR jobs!!
Please read this and take actions accordingly.
In the US study, patients in category 5 showed a 20% improvement in the primary endpoint, and in the Brazil study, a 25% improvement. In the US study, patients in category 5 treated with Abivertinib were discharged from the hospital 2 days sooner than those in the Control Group (8.6 vs. 10.6 days). Overall, in both studies patients who were in category 5, but not in category < 4, showed improvement with Abivertinib treatment. Based upon these preliminary results, a pivotal multi-country, multi-center pivotal Phase 3 study is being planned in 400 patients (randomized 1:1) on the At-Risk Hospitalized COVID-19 Patients requiring oxygen support via non-invasive ventilation or high flow oxygen at baseline (category 5 patients).
“Patients on non-invasive ventilation or high flow oxygen supplementation due to COVID-19-induced respiratory failure represent a sicker and at-risk population with few available treatment options,” stated Dr. Mike Royal, Chief Medical Officer of Sorrento Therapeutics. “Abivertinib has the potential to fill this unmet need and significantly reduce progression to intubation, mechanical ventilation and death.”
Wainright analyst Selvaraji assigns Sorrento a $26 price target - about 400% above current prices! HOWEVER an article reminds us that "...Selvaraju reminds investors that his valuation assessment “does not factor in any contribution” from Sorrento's Covid-19 therapeutics pipeline. These could drive “meaningful upside” to Selvaraju’s forecasts.
The company is currently running several studies testing Covid-19 solutions. These include “multiple” Phase 2 trials in the U.S. and U.K. for COVIDROPS, Sorrento’s intranasal formulation of neutralizing antibody COVI-AMG. Sorrento intends to apply for Emergency Use Authorization (EUA) in several countries, should results prove positive.
There is also COVI-MSC, a proprietary preparation of mesenchymal stem cells (MSCs), earmarked to begin a randomized, controlled clinical study. This drug could also “qualify” for an EUA before the end of the year, dependent on a positive outcome in the study. COVI-MSC is also undergoing Phase 2 testing in Brazil, for which patient enrollment began last month. The coming months should also see the release of top-line data from two Phase 2 trials of abivertinib, a Bruton's tyrosine kinase (Btk) inhibitor being assessed for the treatment of hospitalized COVID-19-infected patients."
COVIDROPS, COVI-AMG, COVI-MSC and ABIVERTINIB (COVID) aren't assigned ANY VALUE? How about another $100 !
JOHN J just posted this...
Brazil Distributor / Partnership News / Breaking news
https://www.facebook.com/medicamentosfutura/photos/2253447184791115
Looks like Sorrento has their partner all set up. We should be getting a PR tomorrow.
Jesspro, I am not aware of any updates. Although I am looking forward to Brazilian results in both hospitalized patients and another trial in Covid long-haulers.
Someone just sent me this thought for the day....
"If we wanted to boldly send Billionaires
where no Billionaires have been before,
We could have just sent them to the Tax Office."
1. Most wealthy nations would like to see 85-90% double vaccination rates.
2. Monoclonal antibodies, anti-virals and stem cell treatments will still be needed.
3. More effective, even safer second generation vaccines are in development.
Sorrento has developed an affordable rapid accurate Covid test(COVISTIX) and has a rapid effective antibody treatment(COVIDROPS), several anti-virals and a powerful rescue stemcell treatment(COVI-MSC) under development. And they are working on second generation broad spectrum vaccines which will be safer and with longer lasting efficacy.
We should soon learn if ABIVERTINIB can prevent or treat cytokine storm as well as treat NSCLC, blood cancers, lupus and MS(can you say "miracle drug").
And COVISTIX revenues from Mexico, Europe, Brazil and Canada have already started to flow and global and regional distribution partnership are being negotiated!
There is a lot of news coming next few weeks!
I would never have guessed that COVISTIX would be the big revenue breakthrough for Sorrento! They are now negotiating worldwide and regional distribution agreements and adding manufacturing capacity! MEXICO, EUROPE and soon CANADA and BRAZIL...and very soon US in my opinion!
Todays FINANCIAL TIMES article..
"US grapples with rapid test crunch as vaccine mandate looms"
...unvaccinated employees must soon submit to weekly checks,straining short supply."
Dr.Ji has pointed out that rapid test prices in the US have increased rapidly. FDA approval of COVISTIX could be sooner than we think!
Why am I loaded up with SRNE?
I expect SRNE will be a 20+ bagger in the next 12 months.
I think NOW is an excellent time to load up. I AM loaded up and ready.
There is a lot of good news coming over the next few weeks and months!
And it starts next week....building on the great COVISTIX news this week! Look at what SRNE has on the new updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico...millions shipped.Europe, Brazil,WHO and Canada coming soon. DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential as soon as August
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of ImmunityBio, Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many approvals and EUA's will produce revenues within weeks in Mexico and soon in Europe, Canada and Brazil. And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
Soon COVISTIX will be approved in Mexico, Europe, Brazil, Latin America and Canada.
THE MARKET SIZE WILL BE OVER ONE AND A HALF BILLION!
Revenues in the Billions.
Sorrento will soon be very unique...a PROFITABLE small biotech!
Cash flow to fund 75+ drug programs!
I won't sell a share for less than triple digits.
I think it is in binding arbitration. Could be wound up any time now. Any awards will be nice...but with COVISTIX revenues coming on stream rapidly it is not a pressing issue IMO.
Another look at todays news...from Reddit
"On the CE Mark: more excitement please!
...
If the headline were EU EUA approval for COVISTIX, the market would have reacted more positively.
There is no 'emergency use' language in this approval because it has met the CE standard to distribute COVI STIX in the EU and anywhere accepting of the CE mark.
This is better than an EUA authorisation: "enables Sorrento to sell this device in all territories that accept the Qarad EC-Rep (Belgium) CE Mark for commercialization "
Enables them to sell in those countries accepting the CE mark: what more do we want? Why want an EUA which is a lower threshold and could be withdrawn when the emergency is technically over?
This is a higher bar! Now, this provides more evidence that the lack of an FDA EUA is not about Sorrento's or Ji's failings but on the FDA side. Mexico and the EU now have authorised covi-stix.
If there has always been a complaint about the EU from business in the uk its this: too much red tape. It's not easy to get things through. I realise this board is american centric, but those europeans here will know getting approval in the EU is no easy task - Sorrento have navigated it: well done Ji."
Note: applies to non eu countries too accepting of CE mark (not sure if uk still qualifies as this looks circa 2016) NNB...some say UK still accepts it until 2023
https://2016.export.gov/cemark/eg_main_017269.asp
COVISTIX approvals in Mexico first, now Europe, with Canada and Brazil coming soon. Sorrento is ramping up production preparing for sales of "tens of millions" of test kits...
Revenue will be substantial this quarter and increase next quarters. And Abivertinib marketing approval in China and SP-102 approval in US will increase revenues substantially.
These are all Blockbuster Billion dollar products...Sorrento is entering a new phase...a profitable Biotech with a huge portfolio of Covid, Cancer and non-opioid Pain products!
Know what you own!
Interesting post from WHATSUP....
"Made the call so now the BS ENDS
CoviStix is IN STOCK and being sold in Mexico but cannot be exported to the States. Sending to Brazil is possible but it has to go through customs and that could be an issue.
Akuasul (Store Front) Could I pick up 10 to 15 boxes there and were they in stock...YES. Very nice people there.
Address
Cuzco
#872, Col. Lindavista Deleg. Gustavo A. Madero, C.P. 07300, Mexico, CDMX
Email
tienda@akuasul.mx
Phone from the USA
011-52-55 5746 7100
A little confusion when I first asked for 10, they said they were only sold by the Box which had 25 tests."
Population of Europe is over 748 million...more than twice that of US.
STIX / ABIVERTINIB / SP102 / DROPS
All have near term news. All have billion dollar markets.
The other 72+ Sorrento programs can be financed by the profits from these 4 programs alone. I was glad to see the new updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico...millions shipped.Brazil,WHO and Canada coming soon. DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential as soon as August
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of ImmunityBio, Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks in Mexico. And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
s
COVISTIX EUA in Mexico alone will produce $100's of millions of revenue in Q4(now)! And we should see EUA's in Canada and Brazil within weeks. Critics will say "So what...we need the US approval!"
NO we don't.
The US approval could also come soon and the US population is about 331 million. However the combined Mexican, Brazilian and Canadian population is about 383 million! That is over 50 million more than the US! The US approval will be nice but Sorrento will already have potential multi-Billion dollar markets underway!
And with multi-Billion dollar SP-102 sales expected to begin in 2H of 2022 Sorrento's other 75 programs will be well funded!
This is bad news for critics but good news for patient longs!
Glad to see the RTX treatment for intractable cancer pain advancing. It was this indication and the cancer drugs that first got me interested in Sorrento. And RTX has several other very large and important applications. This is very good news for cancer patients and their families!
Those who are experienced Biotech investors know that gaining marketing approval for a new drug can often take 5 years or more! Dr Ji took the bold step of producing a Covid portfolio of 16 tests or drugs that could qualify for an EUA.
The first EUA has already been granted in Mexico. Permission has been granted for 25 million CoviStix tests to be sent to Mexico and Dr.Ji has said the first 10 million will soon be on the way. He also said that CoviStix EUA's will soon be granted in Brazil and Canada(within a month).
He also told us that as well as being tested in the UK, Mexico and the US, further COVIDROPS tests are being arranged with several US State governments for large scale tests! COVIDROPS will likely be the next EUA candidate.
Both CoviStix and COVIDROPS are needed around the world so worldwide marketing partnerships could be announced any time. Such a partnership would be worth Multi-Billions in upfront, milestone and royalty payments. Meanwhile there should be very large CoviStix sales beginning in Q4 of this year!
Next year Sorrento can also look forward to SP-102 sales in 2H 2022 and ABIVERTINIB(cancer) revenues from China. All of this revenue will finance Sorrento's very large pipeline and build the $200-400 Billion market Cap company that Dr.Ji has envisioned. I am enjoying the ride!
Ox40 is very important in enhancing T-cell activity....particularly memory T-cells. They help prevent the return of the cancer!
Another important post from Paul
"YOU WANT TO KNOW HOW BIG RELATIONSHIPS PLAY A PART IN BUSINESS IN LATIN AMERICA? HUGE. Sorrentos MX CEO is Hector Sulaiman S.. Ok we know that, now the distribution Company for COVISTIX we found out today is Akuasul. Now here’s the thing folks, do you know who is Deputy Director General of Akuasul? Claudia Sulaiman . I don’t believe in coincidences, and that’s how business gets done. Akuasul is a big manufacturer and distributor, and looking on the website COVISTIX is one of the two latest items to be introduced. I don’t think COVISTIX will be collecting dust on the shelf??"
post from Paul4321
' Easy to schedule a POC antigen test at pharmacy in Mexico. The 3 largest pharmacies are FEMSA Health Division, Farmacias Guadalajara, and Farmacias Benavides. Lera use Benavides as an example. Just go onto website, and find the nearest location. Schedule an appointment, and you’ll get a barcode. You must have the barcode to be tested by a health expert (POC) when you arrive at the pharmacy. The average retail cost is $15-20. As you’ll see on the website the cost is $349 pesos or 16.84 US dollars. So about double the distribution price for the medical field on the Kualsul website. That sounds about right. With the 70 countries MX treaty, and hopefully the Brazil EUA this week or next (though Brazil is probably part of the treaty) my thinking is that huge demand / orders Ji mentioned is actually a reality and not some vague statement. Time will tell, but I think we’re in for a pleasant surprise whether earnings show this quarter or next. "
Abivertinib can apparently be used to treat many cancers, cytokine storm, and will soon enter the clinic for phase two trials in Lupus and MS! And Sorrento has said they are looking to partner it.
The upfront payments, milestones and royalties will be in the Billions!
For 1776...
"Surgeon General Pointed Out George Washington Had His Troops Inoculated and We’ve Been Vaccinated People for So Many Years
Dr. Murthy said first he'd "like to speak about vaccine requirements. In the last few months, more organizations have announced COVID-19 vaccine requirements. And as all of you know, the President recently announced the federal government will be using its authorities and levers to require vaccination for federal workers, healthcare workers, and organizations with a hundred or more employees. I want to make three points today about vaccine requirements," he said. "First vaccine requirements are not new in 1777. President George Washington required soldiers to be inoculated against a small pox in the 1800s. Many public schools began to require vaccination for their students during World War II, the U.S. military required their troops to be vaccinated against a number of diseases, including typhoid, tetanus, and yellow fever for years."
Cheer up! Beer is not good for you.
I've been in SRNE for several years and am up about 300%.
And I'm not selling a share until its in triple digits!
PPS of $500 at least IMO.
Have you ever looked at the potential sales in Sorrento's COVID, PAIN and CANCER and INFLAMMATION portfolios two or three years from now? Make your own judgements. Here are mine.
1. COVID
COVISTIX, COVIDROPS, COVIMSC etc... and second generation booster vaccines and anti-virals. Revenues begin this year. Annual Sales of at least $10 Billion.
2. PAIN
SP-102, SP-103, SP-104 target huge sciatica, back pain and Covid long hauler markets. RTX in Cancer and Arthritic pain. Revenues begin in 2H of 2022. Annual Sales of at least $15 Billion.
3. CANCER + INFLAMMATION
ABIVERTINIB in NSCLC and other solid tumours, and against cytokine storm, lupus and MS. At least 12 ADNAB(Mayo Clinic) indications and dozens of CAR-T, DAR-T and other drugs. Sofusa lymphatic drug delivery system. Revenues begin in 2022. Annual Sales of at least $20 Billion.
Potential market Cap? Multi-Billions!
Merck claims that their anti-viral pill is about 50% effective in preventing hospitalizations and deaths in Covid patients. How might COVIDROPS compare? We have no COVIDROPS published data but competitor Mabs are about 80% effective and Sorrento has suggested that COVIDROPS might improve on that! However competitor Mabs are very expensive and require several hours for infusion in overcrowded infusion centers. COVIDROPS could be administered in a few minutes in the doctors office, the pharmacy or even at home.
What are COVIDROPS advantages compared to competitor Mabs?
1. COVIDROPS efficacy may significantly exceed 80%.
2. They only require 1/50th of the dosage of competitor Mabs. This smaller dosage reduces cost and potential negative adverse events.
3. They can be produced using the the C1 technology. This allows for production runs producing 10 times the quantity of the competitors production adding even more cost savings!
4. They do not require costly hospital or infusion center time.
Just as COVISTIX was first approved in Mexico and will likely be approved next in Brazil, Canada, the UK and Europe, we should expect the same for COVIDROPS. Dr.Ji has stated that they plan to speed up trials in the US by working directly with State governments.
I look forward to international marketing partnerships and worldwide multi-Billion sales!
So if the Merck pill is 50% effective...
and we learn that Abivertinib is 60-70% effective...
and COVIDROPS is 95-98% effective? We should soon hear about both!
Good point. I found the discussion between Dr.Ji and the DYAI CEO was very enlightening and encouraging.